Endocrine Abstracts

Pasireotide, a multireceptor-targeted somatostatin analogue, was approved for the treatment of acromegaly, after being studied in two large, randomised, multi-center clinical trials. We reported the history of a 76 years old man affected by acromegaly, treated with Pasireotide long acting release (LAR) as first line therapy. Acromegaly was diagnosed in 2009, as the result of endocrinological investigation suggested by altered facial appearance and macroglossia. Hormonal assays...

Introduction: Mutations in the aryl hydrocarbon receptor-interaction protein (AIP) gene predisposes to growth hormone or prolactin secretin adenomas, usually, manifesting before the age of 30 years old. There are 834 variants of the AIP reported in the GnomAD database and over 100 variants have been described in patients with pituitary adenomas. While the pathogenic role of variants resulting in truncated protein is beyond doubt, determination of the clinical...

Introduction: In 2004, the WHO defined atypical pituitary adenomas (APAs) those with Ki-67 >3%, excessive p53 expression and increased mitotic activity. The usefulness of this classification is still controversial.Aim: To compare the clinical and prognostic features in a series of typical and atypical pituitary adenomas.Materials and methods: We retrospectively reviewed 343 consecutive PAs. APAs represented 18.7% of the cases. ...

Pituitary tumors are most usual intracranial tumors, displaying hormonal hyper-secretion with in some cases a sustained cell proliferation. The somatotroph adenomas are characterised by a GH hypersecretion. The current treatments are based on somatostatinergic or dopaminergic agonists. Unfortunately, there is steel 50% of patients, which remain insensitive to these treatments. The aim of our work is to find a pharmacological alternative to treat the patients resistant to the c...

Introduction: Treatment of differentiated thyroid carcinoma (DTC) remains a challenge in the setting of locally advanced or metastatic disease refractory to radiodine (RAI) therapy. SELECT trial demonstrated that Lenvatinib improved progression free survival (PFS) comparing to placebo.Objective: Our aim is to report the efficacy and safety of lenvatinib in our population with aggressive DTC.Methods: We retrospectively reviewed the ...

Aim: To evaluate calcium and bone metabolism in a monocentric series of acromegaly patients (pts), treated with pegvisomant (PEG) alone or in association to long acting somatostatine analogs.Patients and methods: All pts with at least 24 consecutive months PEG treatment (alone or in combination with SSA) were enrolled. All pts had been tested at least twice/year for biochemical acromegaly-disease evaluation and annually for calcium metabolism and for bon...

Background and objective: Atypical pituitary adenomas (APA), in 2004, were defined according to WHO classification, as those with Ki-67>3%, excessive p53 expression and increased mitotic activity and invasive behaviour. The real usefulness of this classification is still controversial, so we reviewed compared clinical and prognostic features in our typical and atypical pituitary adenomas.Patients and methods: We retrospectively reviewed 343 consecuti...

GEP NETs, especially gastrinomas, occur in 40–70% of MEN1 patients and represent the main cause of death in these patients.We aim to investigate the efficacy of lanreotide autogel (ATG) in the treatment of MEN1-related gastrinomas.We report a monocentric series of seven MEN1 patients (three M, and four F) treated with lanreotide ATG (120 mg/4 weeks) for a mean period of 62.1 months. Plasma gastrin levels have been measured at ...

Anorexia Nervosa (AN) is a severe eating disorder characterized by significantly low body weight and fear of gaining weight. Amenorrhea is a very frequent feature in AN and it could persist after normalization of BMI. A well-represented fat mass and an adequate body composition (BC) are necessary for resumption of periods. Patients affected by AN, although in the remission phase, fear of becoming fat and refuse to gain weight. In our study we evaluated the effect of a normocal...

The IGF1 response to recombinant human growth hormone (rhGH) showed some individual variability and the responsible factors for this behavior remain unknown. Some studies have emphasized the possible role of isoforms of the GH receptor (GHR), showing conflicting results.Therefore, we investigated the possible influence of the isoforms of the GHR to the diagnosis of GHD and in determining adult hormone replacement therapy responsiveness.<p class="abst...